Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 13/20 | 0.89 |
| ▸ | ECE1 | P42892 | 1/20 | 0.89 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.89 |
| ▸ | CCKBR | P32239 | 1/20 | 0.81 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.79 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.76 |
| ▸ | CCKAR | P32238 | 3/20 | 0.75 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glp-1 SCHEMBL29353361 | 1.00 | GLP1R (0.89) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29462206 | 0.98 | GLP1R (0.88) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29366649 | 0.98 | GLP1R (0.88) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29360422 | 0.98 | GLP1R (0.88) | GLP1RECE1MUS81CCKBRNR3C1 | |
| Oxyntomodulin SCHEMBL29349603 | 0.95 | GLP1R (0.84) | GLP1RECE1MUS81CCKBRNR3C1 | |
| Liraglutide SCHEMBL29350802 | 0.94 | GLP1R (1.00) | GLP1RECE1MUS81CCKAR | |
| Liraglutide SCHEMBL20511941 | 0.94 | GLP1R (1.00) | GLP1RECE1MUS81CCKAR | |
| SCHEMBL29942531 | 0.94 | GLP1R (0.78) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL31099271 | 0.93 | GLP1R (0.84) | GLP1R | |
| SCHEMBL28662518 | 0.93 | GLP1R (0.84) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |